Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $4.00 price objective on the stock.

Separately, Wall Street Zen downgraded Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $4.00.

Actinium Pharmaceuticals Stock Performance

Shares of NYSE ATNM opened at $1.62 on Tuesday. Actinium Pharmaceuticals has a fifty-two week low of $1.03 and a fifty-two week high of $8.64. The firm has a market capitalization of $50.54 million, a PE ratio of -1.17 and a beta of -0.27. The stock’s 50-day simple moving average is $1.55 and its 200-day simple moving average is $1.36.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATNM. Gagnon Securities LLC purchased a new position in Actinium Pharmaceuticals during the 1st quarter worth approximately $365,000. Nuveen LLC purchased a new position in shares of Actinium Pharmaceuticals in the 1st quarter valued at approximately $239,000. Invesco Ltd. grew its stake in shares of Actinium Pharmaceuticals by 1,135.9% in the 1st quarter. Invesco Ltd. now owns 153,555 shares of the company’s stock valued at $247,000 after purchasing an additional 141,130 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Actinium Pharmaceuticals by 804.5% in the 4th quarter. JPMorgan Chase & Co. now owns 123,831 shares of the company’s stock valued at $156,000 after purchasing an additional 110,141 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of Actinium Pharmaceuticals by 413.6% in the 4th quarter. Deutsche Bank AG now owns 123,134 shares of the company’s stock valued at $155,000 after purchasing an additional 99,158 shares during the last quarter. Hedge funds and other institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).